tiprankstipranks
Aehr Test (AEHR)
NASDAQ:AEHR
Want to see AEHR full AI Analyst Report?

Aehr Test Systems (AEHR) AI Stock Analysis

1,923 Followers

Top Page

AEHR

Aehr Test Systems

(NASDAQ:AEHR)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
$69.00
▼(-9.59% Downside)
Action:Reiterated
Date:07/16/26
AEHR scores highest on forward-looking outlook from the earnings call: aggressive FY27 growth/profitability guidance backed by record bookings/backlog and stronger liquidity. This is offset by weaker recent financial performance (losses and cash burn) and an unfavorable valuation signal from a negative P/E, while technical indicators are broadly neutral/mixed.
Positive Factors
Strong liquidity and capital cushion
Aeher's sizable cash balance after the ATM raise provides multi-quarter runway to fund capacity expansion, R&D, and customer ramps without immediate external financing. This materially reduces execution risk during a planned multi-fold revenue ramp and supports capital-intensive production scaling.
Negative Factors
Volatile revenue and recent cash burn
The company has swung from profitable periods to consecutive years of negative operating and free cash flow, indicating execution sensitivity. Continued cash burn during scaling raises funding reliance and magnifies the impact of missed bookings or shipment delays on long-term financial durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and capital cushion
Aeher's sizable cash balance after the ATM raise provides multi-quarter runway to fund capacity expansion, R&D, and customer ramps without immediate external financing. This materially reduces execution risk during a planned multi-fold revenue ramp and supports capital-intensive production scaling.
Read all positive factors

Aehr Test Systems Key Performance Indicators (KPIs)

Any
Any
Bookings
Bookings
Measures new orders received for Aehr’s test and burn-in systems, indicating current demand and the pipeline for future revenue. Large or growing bookings point to customer adoption and potential near-term revenue ramps, while volatility can signal project timing, long lead times, or reliance on a few big customers.
Chart InsightsBookings are highly lumpy—periodic multi‑million spikes driven by a few large system orders and product ramps, followed by shallow quarters—so revenue depends on timing of big wins. Management’s H2 $60–$80M bookings visibility and recent Sonoma orders make a strong FY27 plausible, but much of that is customer forecasts (not firm POs) and technical delays (GaN, silicon photonics) create meaningful execution/timing risk. Treat the guidance as conditional upside tied to conversion of backlog/forecasts into firm orders rather than a certainty.
Data provided by:The Fly

Aehr Test Systems (AEHR) vs. SPDR S&P 500 ETF (SPY)

Aehr Test Systems Business Overview & Revenue Model

Company Description
Aehr Test Systems, founded in 1977 and based in Fremont, California, specializes in the global provision of advanced burn-in and test systems for integrated circuits, encompassing logic, optical, and memory devices. Its extensive product lineup in...
How the Company Makes Money
Aehr generates revenue primarily by selling semiconductor test and burn-in systems and the related consumables and services required to run those systems. Key revenue streams include: (1) Test and burn-in systems: Sales of capital equipment platfo...

Aehr Test Systems Earnings Call Summary

Earnings Call Date:Jul 14, 2026
(Q4-2026)
|
% Change Since: |
Next Earnings Date:Oct 01, 2026
Earnings Call Sentiment Positive
The call highlighted multiple strong operational and commercial positives: record bookings and backlog, robust Q4 revenue and margin expansion, large hyperscaler and AI customer momentum, successful technical benchmarks (including with a major AI processor supplier), technological milestones (300mm GaN), a much stronger cash position, and expanded manufacturing capacity. These positives underpin an aggressive FY27 revenue and profitability outlook. Headwinds include FY26 full-year revenue and margin declines, ongoing litigation costs, supplier/parts cost and lead-time pressures, higher operating expenses, and continued uncertainty around some end markets (silicon carbide recovery and memory opportunities). Overall, the constructive commercial wins, backlog, cash runway, and explicit guidance for substantial growth materially outweigh the lowlights, supporting a positive outlook for fiscal 2027, while acknowledging execution and supply-chain/legal risks that could affect delivery.
Positive Updates
Record Quarterly Bookings and Backlog
Q4 bookings were $60.7M, up more than 500% YoY (from $11.1M). Year-end backlog was a record $80.6M (vs $15.2M a year earlier) and increased to an effective ~$100.6M after ~$20M of subsequent bookings.
Negative Updates
Full-Year Revenue Decline and Margin Compression
FY26 revenue was $50M, down 15% YoY. Full-year non-GAAP gross margin declined to 38.5% from 44% in the prior year (down ~5.5 percentage points), and full-year non-GAAP net income fell to $0.9M ($0.03/share) from $4.6M ($0.15/share) in FY25.
Read all updates
Q4-2026 Updates
Negative
Record Quarterly Bookings and Backlog
Q4 bookings were $60.7M, up more than 500% YoY (from $11.1M). Year-end backlog was a record $80.6M (vs $15.2M a year earlier) and increased to an effective ~$100.6M after ~$20M of subsequent bookings.
Read all positive updates
Company Guidance
Management guided fiscal 2027 revenue of $130 million to $150 million (2.6x–3x the just-completed fiscal 2026 revenue of $50M; ~160%–200% growth year‑over‑year), with non‑GAAP pretax profitability of 18%–22% of revenue; the outlook is based on current backlog and customer forecasts, they say they are not capacity‑limited at the $150M level and could raise guidance if more orders materialize. Key supporting metrics disclosed on the call included record Q4 bookings of $60.7M (up >500% vs. $11.1M a year ago), year‑end backlog of $80.6M plus ~$20M of subsequent bookings (effective backlog ≈ $100.6M), Q4 revenue of $18.8M (up 34% YoY) and full‑year revenue of $50M (down 15% YoY). Profitability and cash metrics highlighted were Q4 non‑GAAP gross margin of 45% (+1,000 bps vs. prior year Q4’s 35%), full‑year non‑GAAP gross margin of 38.5% (vs. 44% prior year), Q4 non‑GAAP net income of $3.6M or $0.11 per diluted share (vs. a non‑GAAP loss last year), full‑year non‑GAAP net income of $0.9M or $0.03, cash and equivalents of $116.5M (vs. $26.5M a year ago) after raising about $100M (ATM), and only $2.1M of capex in fiscal 2026.

Aehr Test Systems Financial Statement Overview

Summary
Financials are mixed. The balance sheet is strong (low leverage and substantial equity), but operating results have been volatile with a swing from strong profitability to recent losses, and cash generation has deteriorated with negative operating and free cash flow in the last two annual periods.
Income Statement
42
Neutral
Balance Sheet
78
Positive
Cash Flow
35
Negative
BreakdownMay 2026May 2025May 2024May 2023May 2022
Income Statement
Total Revenue50.00M58.97M66.22M64.96M50.83M
Gross Profit17.65M23.93M32.54M32.75M23.66M
EBITDA-11.74M-903.00K13.82M15.07M9.85M
Net Income-7.13M-3.91M33.16M14.56M9.45M
Balance Sheet
Total Assets246.69M148.51M127.91M98.14M62.33M
Cash, Cash Equivalents and Short-Term Investments116.36M25.23M49.16M47.91M31.48M
Total Debt9.88M10.83M6.20M6.30M1.01M
Total Liabilities27.18M25.64M16.32M22.54M11.34M
Stockholders Equity219.51M122.87M111.59M75.60M50.99M
Cash Flow
Free Cash Flow-5.38M-12.39M1.01M8.65M1.09M
Operating Cash Flow-3.31M-7.40M1.76M10.01M1.51M
Investing Cash Flow-3.87M-16.07M17.25M-18.66M-416.00K
Financing Cash Flow97.21M625.00K139.00K7.32M25.76M

Aehr Test Systems Technical Analysis

Technical Analysis Sentiment
Positive
Last Price76.32
Price Trends
50DMA
91.28
Positive
100DMA
80.14
Positive
200DMA
53.41
Positive
Market Momentum
MACD
-2.36
Negative
RSI
54.74
Neutral
STOCH
50.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEHR, the sentiment is Positive. The current price of 76.32 is below the 20-day moving average (MA) of 78.64, below the 50-day MA of 91.28, and above the 200-day MA of 53.41, indicating a bullish trend. The MACD of -2.36 indicates Negative momentum. The RSI at 54.74 is Neutral, neither overbought nor oversold. The STOCH value of 50.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AEHR.

Aehr Test Systems Risk Analysis

Aehr Test Systems disclosed 1 risk factors in its most recent earnings report. Aehr Test Systems reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aehr Test Systems Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
60
Neutral
$2.61B-347.74-4.66%-15.21%-81.50%
56
Neutral
$2.26B-57.74-4.87%32.66%55.60%
53
Neutral
$2.62B-50.81-7.50%7.53%-203.93%
48
Neutral
$949.96M-8.91-12.98%0.60%-359.56%
47
Neutral
$3.73B-19.42-28.05%-3.24%-786.94%
45
Neutral
$732.90M-4.19-42.36%0.17%-1.78%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AEHR
Aehr Test Systems
91.71
72.68
381.92%
AOSL
Alpha and Omega
31.47
5.34
20.44%
COHU
Cohu
48.84
29.97
158.82%
UCTT
Ultra Clean Holdings
89.17
65.87
282.70%
ICHR
Ichor Holdings
80.23
60.09
298.36%
INDI
indie Semiconductor
3.39
-0.42
-11.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 16, 2026